Abstract

Background: Pulmonary hypertension (PH) is a rare progressive and lethal disease affecting pulmonary arteries and heart function. The disease may compromise the nutritional status of the patient, which impairs their physical performance. This study aimed to determine the prevalence of micronutrient deficiencies in pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) patients. Methods: Eighty-one blood samples from a prospective observational cohort study were analyzed for concentrations of micronutrients and inflammation-related factors. The samples consisted of newly diagnosed (treatment-naive) PAH and CTEPH patients and patients treated for 1.5 years according to ERS/ESC guidelines. Results: In the newly diagnosed group, 42% of PAH patients and 21% of CTEPH patients were iron deficient compared to 29% of PAH patients and 20% of CTEPH patients in the treatment group. Vitamin D deficiency occurred in 42% of the newly diagnosed PAH patients, 71% of the newly diagnosed CTEPH patients, 68% of the treated PAH patients, and 70% of the treated CTEPH patients. Iron levels correlated with the 6 min walking distance (6MWD). Conclusions: Iron and vitamin D deficiencies are highly prevalent in PAH and CTEPH patients, underlining the need for monitoring their status. Studies evaluating the effects of supplementation strategies for iron and vitamin D are necessary.

Highlights

  • Pulmonary hypertension (PH) refers to a heterogeneous group of diseases characterized by vasoconstriction and structural remodeling of the pulmonary arteries

  • We focused on patients with World Health Organization (WHO) type 1: pulmonary arterial hypertension (PAH) and type 4: chronic thrombo-embolic pulmonary hypertension (CTEPH), because these patients are typically treated with PH-specific therapies in expert centers

  • There were no differences in age, weight, body mass index (BMI), 6 min walking distance (6MWD), right ventricular systolic pressure (RVSP)

Read more

Summary

Introduction

Pulmonary hypertension (PH) refers to a heterogeneous group of diseases characterized by vasoconstriction and structural remodeling of the pulmonary arteries. We focused on patients with WHO type 1: pulmonary arterial hypertension (PAH) and type 4: chronic thrombo-embolic pulmonary hypertension (CTEPH), because these patients are typically treated with PH-specific therapies in expert centers. In both categories, the pathophysiology originates in the pulmonary arteries. This study aimed to determine the prevalence of micronutrient deficiencies in pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) patients. The samples consisted of newly diagnosed (treatment-naive) PAH and CTEPH patients and patients treated for 1.5 years according to ERS/ESC guidelines. Studies evaluating the effects of supplementation strategies for iron and vitamin D are necessary

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.